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Heterotrimeric GTP-binding proteins (G-proteins) 
serve many different signal transduction pathways. 
Phosducin, a 28-kDa phosphoprotein, is expressed in a 
variety of mammalian  cell  types and blocks activation of 
several classes of G-proteins.  Phosphorylation of phos- 
ducin by  cyclic =-dependent protein kinase prevents 
phosducin-mediated inhibition of G-protein GTPase ac- 
tivity  (Bauer, P. H., Miiller, S., Puzicha, M., Pippig, S., 
Obermaier, B., Helmreich, E. J. M., and Lohse, M. J. 
(1992) Nature 358, 73-76). In retinal rods,  phosducin in- 
hibits transducin (G,) activation by binding its Py sub- 
units. While rod phosducin is phosphorylated in the 
dark  and dephosphorylated after illumination  (Lee, R.- 
H., Brown, B. M., and Lolley, R. N. (1984) Biochemistry 23, 
1972-1977), the significance of these reactions is still un- 
clear.  The data presented here permit a more  precise 
characterization of phosducin function and the conse- 
quences of its phosphorylation. 
Dephosphophosducin  blocked  binding of the G,a‘ sub- 
unit to activated rhodopsin in the presence of stoichio- 
metric amounts of G,P y, whereas  phosphophosducin  did 
not.  Surprisingly, the binding affinity of phosphophos- 
ducin for G,Py was  not  significantly  reduced  compared 
with the binding  affinity of dephosphophosducin. How- 
ever, the association of phosducin  with G,Py in a size 
exclusion  column  matrix  was dependent on the phos- 
phorylation state of phosducin. Moreover, the ability of 
phosducin to compete  with G,a for binding to G,& was 
also dependent on the phosphorylation state of phosdu- 
cin. No interaction was  found  between  phosducin and 
G,a. These data indicate that phosducin  decreases  rod 
responsiveness by binding to the Py subunits of G, and 
preventing their interaction with G,a, thereby inhibit- 
ing G,a activation by the activated receptor.  Moreover, 
phosphorylation of phosducin  blocks its ability to com- 
pete with G,a for binding to G,&. 
Heterotrimeric G-proteins comprise a gene family whose 
members  function in a remarkable  variety of signal transduc- 
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tion  pathways.  Binding of G-proteins  to  their  activated  recep- 
tors results in exchange of GDP  for  GTP and dissociation of the 
GTP-bound Ga  subunit  from its GP-y subunits. Activated  Gas 
(GwGTP‘s) regulate a variety of effector  protein  systems, in- 
cluding cyclic nucleotide  processing  enzymes,  phospholipases, 
and cation-selective  channel  proteins (for review, see Refs. 1-3). 
In addition, GP-y subunits have  recently  been  shown  to  regulate 
directly effectors such as phospholipase A, (4), P-adrenergic 
receptor  kinase (5), type I1 adenylyl  cyclase (6, 7) and  phospho- 
lipase C-P (8,9). GTP  hydrolysis  by  Ga  allows  the  reassociation 
of Ga-GDP  with GP-y, returning the system  to its ground  state 
in which G a p y G D P  is again  capable of binding  to an activated 
receptor. 
Phosducin is a highly  conserved  28-kDa  phosphoprotein that 
is expressed in a number of cell types  including retinal rods and 
cones,  pinealocytes,  neurons,  hepatocytes,  and  myocytes (10- 
13). Moreover, the retinal protein MEKA was  found  to be vir- 
tually  identical  to  phosducin  from retina and brain (11, 12,  14). 
Phosducin inhibits the GTPase activities of a number of G- 
proteins  including Gi, G,, and  Go (12); phosphorylation of phos- 
ducin  with cyclic AMP-dependent  protein  kinase  prevents this 
GTPase  inhibition (12). Phosducin  was  first  isolated in verte- 
brate  retinal  rod  cells in a complex  with GJ3-y subunits (151, and 
i t  has been  proposed that phosducin  interferes  with  transducin 
(GJ  function  by  binding  to G$-y (16).  While  rod  phosducin is 
known  to be phosphorylated in the dark  and  dephosphorylated 
after illumination (171, the functional significance and bio- 
chemical details of these  phosphorylation  and  dephosphoryla- 
tion  reactions  have  not  been  well defined. Here  we  report  new 
observations that permit a more  precise  characterization of the 
functional  biochemistry of rod  phosducin and the consequences 
of its phosphorylation. 
EXPERIMENTAL PROCEDURES 
Preparation of Bovine Rod Outer Segments -Rod outer segments 
(ROS)  were prepared by sucrose floatation (18). All manipulations of 
dark-adapted retinas were  performed under infrared illumination using 
infrared image converters. Briefly,  250 fresh dark-adapted bovine reti- 
nas (J.A. & W.L.  Lawson Co., Lincoln,  NB)  were suspended in  the  dark 
in 400  ml of HEPESRinger’s buffer  (10 mM HEPES pH  7.5,  120 mM 
NaC1, 3.5 mM KC1, 0.2 m CaCl,,  0.2 mM MgCl,, 0.1 mM EDTA, 10 mM 
glucose, 1 mM DTT,  0.2 ~ l l ~  PMSF) plus 45%  (w/w) sucrose and disrupted 
by being drawn twice through a 60-ml syringe with a 0.7-cm diameter 
orifice. The disrupted retinas were passed through two layers of cheese- 
cloth, and the  retinal material that did not pass through the cheesecloth 
was supended in 50 ml of HEPESRinger’s buffer, drawn through the 
syringe again, and reapplied to the cheesecloth. This process  was re- 
peated three times. The retinal material that did not pass through the 
cheesecloth  was used for phosducin purification. The filtrate from the 
cheesecloth  was centrifuged for  10  min at 4,000 x g. The resulting pellet 
was used for  phosducin purification, and  the  supernatant, containing 
the ROS, was diluted to -15% sucrose with HEPESminger’s buffer. 
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This  suspension  was  centrihged at 10,000 x g  for 20 min.  The  resulting 
supernatant  was  used  for  phosducin  purification,  and  the  pellet  was 
suspended  in  HEPESRinger's buffer, layered  over 15 ml of  33% (w/w) 
sucrose in 6-8 tubes,  and  centrifuged at 40,000 x g  for 15 min.  The  ROS 
were collected from the top of the 33% sucrose  layer,  diluted  to -15% 
sucrose  with  HEPESRinger's,  and  centrifuged at 25,000 x g for 10 min. 
From  these ROS, G, subunits  and  urea-stripped ROS membranes  were 
prepared. 
Protein  Purifications and  Membrane Preparations-Gp, G,py, and 
urea-stripped  ROS  membranes  were  prepared as described  (19)  except 
that  after  separation of  G, subunits on a Blue  Sepharose  column  (Phar- 
macia Biotech Inc.), the subunits were further purified with a high 
performance  liquid  chromatography  (HPLC)  size  exclusion  column (Bio- 
Silect  SEC-250, Bio-Rad) by isocratic  elution in 10 rn HEPES  pH 7.4, 
500 mM NaCI, 5 mM MgCl,, 1 mM EDTA, 1 mM Dm,   and  0.1 m~ PMSF 
(buffer A). The  resulting G,py was >98% pure  and  was  free of G,a as 
determined  by  sodium dodecyl sulfate-polyacrylamide  gel  electrophore- 
sis (PAGE). The G p  was >95% pure and was likewise free of G$y 
subunits. G,a and G,py were labeled with lZ5I using Bolton-Hunter 
reagent  (DuPont  NEN) as described  previously  (19). 
Phosducin was purified by a modification of previously described 
procedures (11, 15).  The  retinal  debris  retained on the cheesecloth  was 
released  and homogenized in 5 mM TrisC1,  pH  7.5,  62 mM NaC1, 5 mM 
MgCI,, 2 p~ leupeptin, and 2 p~ pepstatin A in a Potter-Elvehjem 
homogenizer. The  homogenate  was  centrifuged at 48,000 x g for 10 min; 
the  supernatant  was  saved  and  the  pellet  was homogenized once more. 
The pellet from the 45% sucrose centrifugation step above was also 
homogenized twice.  The  supernatants  were combined with  the  super- 
natant from the 15% sucrose  centrifugation  step (-2 liters),  and pro- 
teins  were  precipitated by the  addition of 474 gAiter ammonium  sulfate. 
The  solution  was  centrifuged at 30,000 x g for 25  min,  and  the  pellet 
was  resuspended  in  30 rn potassium  phosphate,  pH 7.0, 1 mM DTT, 1 
m~ EDTA, and 0.1 mM PMSF  (buffer B). The  suspension  was  dialyzed 
overnight  against 9 liters of buffer  B  with  one  change of buffer  after 6 
h. The suspension was adjusted to pH 5.7 with 1 M acetic acid and 
centrifuged at 48,000 x g for 20 min.  The  pH  and  the  conductivity of the 
solution  were  adjusted  to 7.0 and 6 millisiemendcm, respectively, and 
loaded at 4 mumin at 4 "C on TSK-Gel DEAE Toyopearl 650  M (Toso- 
Haas) column material packed in an HR16/50 column (Pharmacia), 
using a Pharmacia  fast  protein  liquid  chromatography  system.  After  the 
unbound  material  was  washed  through  with  buffer B, phosducin  was 
eluted with 600 ml of a linear gradient from 30-500 mM potassium 
phosphate  in  buffer  B a t  a flow rate of 4.5 ml/min.  The  fractions  with 
conductivities between 13 and 31 millisiemenskm were pooled and 
dialyzed  against 10 rn potassium  phosphate,  pH 7.0, 1 mM D m ,  and 
0.1 mM PMSF (buffer C). The solution was loaded onto Macro-Prep 
ceramic  hydroxyapatite  (40  pm,  Bio-Rad) column material packed in  an 
XK26/40 column  (Pharmacia)  equilibrated  with  the  buffer  C  using  fast 
protein  liquid  chromatography a t  a flow rate of 3 mumin at  4 "C. The 
phosducin  was  eluted  with  300  ml of a linear  gradient of buffer  C to 
buffer  B  containing 150 mM potassium  phosphate,  pH 7.0, a t  3 mumin. 
Fractions  with  conductivities of G 1 4  millisiemendcm  were pooled and 
concentrated to -1.5 ml with CentriPreplO (Amicon) concentrators. 
The  concentrated  phosducin  fraction  was  chromatographed on a  TSK 
G3000SW size  exclusion  column  (TosoHaas, 21.5 mm  (inner  diameter) x 
30  cm  with a 21.5  mm  inner  diameter x 7.5 cm guard  column)  running 
isocratically  with  buffer  A at 5 mumin  using a Waters 625LC HPLC 
system at 23 "C. The phosducin-G,py complex eluted a t  18 min.  Phos- 
ducin  was  separated from G,py and  other  contaminants by strong  anion 
exchange chromatography using a Poros Q/M 4.6/100 column (Per- 
Septive  Biosystems).  The  column  was  equilibrated in 50 mM Tris, pH 
8.0, 0.1 mM PMSF, and 1 m~ DTT  and  was  eluted by a linear  gradient 
of  50-750 m~ Tris at 3 mUmin (30 ml).  The  phosducin  eluted at -560 
mM Tris. Phosducin  was  further  purifed by sucrose  density  gradient 
centrifugation (5  ml of 5-20% sucrose, 100 mM potassium  phosphate, 
pH 7.4,2 mM MgCl,, 1 mM EDTA, 1 mM D m ,  0.1 mM PMSF, and - 0.5 
mg of proteidtube)  in a Beckman SW 55Ti rotor  running  in a Beckman 
L8-70 M  centrifuge for 15.3  h at 53,000 rpm (w2t = 1.7 x 10" rad%) at 
4 "C. This phosducin  was 95% pure  and  was  free of G,py as  determined 
by SDS-PAGE and  Western  blotting  with a peptide-specific antibody for 
GJ3. Protein concentrations were determined using Coomassie Plus 
protein  assay  reagent  (Pierce  Chemical Co.). 
Phosducin  Phosphorylation and  Isoelectric Focusing-Phosducin was 
phosphorylated with the  catalytic  subunit of bovine heart CAMP&- 
pendent  protein  kinase  (Fluka)  as follows. Phosducin (30 p ~ )  was  mixed 
with  cAMP-dependent  protein  kinase (1 uniupl)  and ATP (0.5 mM) in 50 
mM HEPES,  pH  7.5,  5 mM MgCI,, 1 nm EDTA, 1 mM D m ,  and 0.1 mM 
PMSF  and  incubated for 10 min at 23 "C. Phosphophosducin  was  im- 
mediately  assayed  for 1251-G,a binding  (see below). For  isoelectric focus- 
ing,  phosducin  was  phosphorylated as described  above in  the presence 
of 0.5 mM (-1000 dpdpmol) [33PlATP, and  then focused on a  flat bed 
isoelectric  focusing gel (0.4  mm)  according to the  manufacturer's (Bio- 
Rad) protocol using  Pharmalyte 4.5-5.4 ampholines  (Pharmacia)  in  the 
presence of 8 M urea.  The gel was fixed in 20% trichloroacetic acid for 30 
min.  Ampholines  were  eluted from the gel by incubating  in  0.25%  SDS, 
10% acetic acid, and 40% methanol for 30  min followed by 10% acetic 
acid and 40% methanol for 1 h.  The gel was  stained  with 0.12% Coo- 
massie  Brilliant  Blue  R  (Serva)  in 10%acetic acid and 40% methanol for 
30  min  and  then  destained  in  the  same  solution  without Coomassie 
Blue. Finally, the gel was  autoradiographed  to verify the incorporation 
of phosphate  into  phosducin. 
Binding of lZ5I-G,a to Rho* in ROS Membranes-Light-induced bind- 
ing of IZ5I-G,a and G,py to urea-stripped ROS membranes  was  carried 
out as described (19). Dephospho- or  phosphophosducin, at the concen- 
trations indicated, was mixed with 0.1 PM 1251-G,a and 0.1 p~ G,Py 
before the addition of urea-stripped membranes in the dark. Light- 
induced binding was then initiated by bleaching 50% of the Rho. 
Samples  were  centrifuged,  and  the  amount of '"I-Gp bound was  quan- 
tified as described (19). 
Phosducin  Inhibition of *251-G,py Binding to ROS Membranes-The 
effect of phosducin on the  binding of 1251-Gtpy to  urea-stripped ROS 
membranes  was  measured by incubating  0.35 p~ 1251-G,py with  increas- 
ing  concentrations of phosducin  in isotonic buffer (10 mM HEPES,  pH 
7.5, 100 mM KCl, 20 mM NaCl,  1.5 mM CaCl,, 1 mM EDTA, 1 m~ DTT, 
and  0.2 mM PMSF) for 10 min at 23 "C. Unilluminated  urea-stripped 
membranes, a t  40  p~ Rho, were  then  added  in  the  dark,  and  the mix- 
ture  was  incubated  in  the  dark for 10  min.  The  final  sample volume was 
50 pl.  For  phosphophosducin,  0.5 unitdpl of CAMP-dependent protein 
kinase,  and 0.5 mMATP were  added  to  phosducin  in  isotonic buffer, and 
phosphorylation  was allowed to  continue for 5 min before the  addition 
of the 1251-G,py and  dark  urea-stripped  membranes.  During  the  dark 
incubation,  20  pl of the  sample  were  taken  and  counted for to  obtain 
the  total  counts,  The  samples  were  then  centrifuged a t  50,000 x g  for 20 
min  to  pellet  the  membranes,  and 20 pl of the  supernatant were  re- 
moved and  counted for lZ5I. The  amount of  1251-G,py in  the  membrane 
pellet  was  calculated by subtracting  the  supernatant  counts from the 
total  counts  in  the  sample.  During  these  experiments,  the  phosphoryl- 
ation  state of phosducin  was  monitored in  parallel  samples  that  were 
incubated  with 0.5 mM [32PlATP (500 cpndpmol). Incorporation of 32P 
into  phosducin  was  quantified by precipitating  10  pl of the  sample  in 
100 p1  of 20% trichloroacetic acid, filtering  through  type HA nitrocellu- 
lose filters  in 96-well Multiscreen  filtration  plates (Millipore), washing 
three  times  with 100 pl of 20% trichloroacetic acid, and  counting  the 32P 
on the filter.  Phosducin  was completely phosphorylated by 2  min  and 
remained  phosphorylated  throughout the experiment.  Control  samples 
without  phosducin  were run  in  order  to  correct for phosphorylation of 
the  urea-stripped  membranes  under  these  conditions. 
In order to  obtain a binding constant for the interaction between 
1251-Gtpy and phosducin, an equation for the binding of lZ5I-G,py to 
urea-stripped ROS membranes as a  function of the  total  concentration 
of phosducin  was  derived  from the following model (Equation I), which 
describes in  simplest  terms  the  binding of  1251-G,py to  the  membrane 
K d l  
lZ5I-G,py + M FZ M,lz5I-G,py 
+ 
Pd 
I t  K d 2  
(Eq. 1) 
Pd.lZ5I-G,py 
where  M  is  the  membrane  binding  site specific for 1251-G,py, and  Pd  is 
phosducin.  From the expressions for the dissociation  constants, 
Kdl = [MI['*'I - G,~yl/[M~'251-G,~y]  (Eq. 2) 
K d 2  = [Pdl[1251 - G t ~ ~ l / [ P d ~ 1 2 5 1 - G , ~ ~ ]  (Eq. 3) 
and  the  expressions for the conservation of mass, 
[MI, = [M~1z51-Gtp~l + [MI (Eq.  4)
[Pdl, = [Pd.1251-Gt/3y] + [Pd]  (Eq. 5) 
[1251-G,~~I, = [M.1251-G,pyI + [Pd~1251-G,~y] + [1251-G,py] 0%. 6) 
an expression for [M.'251-G,pyl was derived in the form of a cubic 
equation. 
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A[M.'2sI-G,py13 + B[M.'2sI-G,py]2 + C[M.'251-G,py] + D = 0, where 
A = Kd2 - Kd1 
B = - KdlKcIz - Kcfl[Pdl, + K,,l[MI, - 2KJM1, + 
K~I['*'II-G,PYI, - K,fJ'ZsI~G,P~l, 
C = KdlKJnl, + Kd,[Pdl,[MI, + KJMI,' - 
K,,,I""I-G,~YI,[MI, + 2K,J'2SI-G,P~l,[MI, 
D = -K,~2('2'I-G,p~l,[M1~ 
The  equation  was solved numerically by Newton's method  and  was 
used to  curve fit the  data for the  binding of 12'I-G,py to  membranes  in 
the presence of phosducin.  The  values of ['?"I-G,pyJ, (0.35 p ~ )  and [Pdl, 
(varied from 0 4 . 8  p ~ )  were known from the  experimental  conditions, 
and initial values of Kd, (2.0 p ~ )  and [MI, (2.4 p ~ )  were obtained in 
separate "'I-G,py binding  experiments  in  the  absence of phosducin. The 
curve fits of the  data yielded best-fit  values for K,,, K,,*, and [ M I , .  The 
experimental  data showed saturation  values  that  deviated from zero by 
-8%- (see  Fig. 4A) due  to nonspecific interactions of '*'I-G,py with  the 
membrane  or low affinity  binding of phosducin-'2'I-G,py to the mem- 
brane. In order for Equation 7 to predict saturation a t  [M.'2'II-Gtpy] 
values  greater  than zero, [MI, was defined as: [MI, = [MI,,, - [MI,,,, 
where [MI,, is  the  total  concentration of membrane  binding  sites  and 
[MI,, is  the concentration of nonspecific binding  sites. 
Effect of G,a on Phosducin  Inhibition of 12'I-Gfpy Binding to ROS 
Membranes-In the same experimental format used in the previous 
section,  2 PM phosducin  was  added  to  increasing  concentrations of Gta 
followed by 0.35 p~ '*'I-G,py, and then unilluminated urea-stripped 
ROS (40 pv Rho)  were  added  in the  dark.  The fraction of  '*'I-G,py in  the 
supernatant  and  the  extent of phosducin  phosphorylation  were  quan- 
tified as described above. 
Effect of Phosducin on 12sI-G,(r Binding to ROS Membranes-In a 
similar experimental format, increasing concentrations of phosducin 
were  added  to 0.35 p~ '2sI-G,a followed by 40 p~ Rho in  heat-denatured 
urea-stripped ROS membranes. The urea-stripped membranes were 
heat  denaturated  at 70 "C for 5 min  prior  to the  addition of "'I-Gp and 
phosducin to remove residual  amounts of G,py from the  membranes 
(see "Results"). 
Gel Analysis of G,a, G,py and  Phosducin Binding to ROS Mem- 
branes-Phosducin (4 p ~ )  was mixed with G,py (6 PM) in  the presence 
or  absence of G,a (16 p ~ )  in isotonic buffer. The  mixture  was  incubated 
with  unilluminated  urea-stripped ROS membranes (40 p~ Rho) for 10 
min  in  the  dark a t  23 "C. The  samples  were  centrifuged a t 50,000 x g  for 
20 min. The  membrane  pellets  were  resuspended  in  the  dark  with 500 
p1 of hypotonic buffer (10 mM HEPES,  pH 7.5, 1 mM EDTA, 1 mM DTT, 
and  0.2 mM PMSF)  and  incubated for 30 min a t  23 "C. The  suspension 
was again centrifuged a t  50,000 x g for 20 min, and the resulting 
supernatant was concentrated to 35 p1 using Microcon 10 (Amicon) 
concentrators. 15 pl of the concentrated supernatant were  analyzed by 
SDS-PAGE on a  12%  Laemmli gel (20).  The gel was  stained  with 0.12% 
Coomassie  Brilliant  Blue  R  (Serva)  in 10% acetic acid and 40% meth- 
anol for 30 min  and  then  destained  in  the  same  solution  without Coo- 
massie Blue. 
HPLC Size Exclusion Chromatography-A Bio-Silect SEC 250-5 
(Bio-Rad) size exclusion column was  used for analytical HPLC analysis. 
The  column  matrix  consists of a  silica-based gel. Samples  containing 
phosducin,  phosphophosducin, G,py and G,a! (as indicated  in  the  figure 
legends) were injected into the column and eluted isocratically with 
buffer  A a t  a flow rate of 1.0 mumin.  Protein  peaks  were  detected by 
measuring  the absorbance of the  eluate at 254 nm.  Fractions from the 
column were pooled as  indicated and concentrated in Centricon 10 
(Amicon) microconcentrators,  and  equivalent  volumes  were  analyzed by 
12'70 SDS-PAGE (20). For phosducin plus G,Py samples,  the  proteins 
were mixed and  incubated for 5 min a t  23 "C before injection. Phos- 
phophosducin  plus  G,py  was  prepared by phosphorylating  phosducin as 
described above and  then  adding G& and  incubating for 5 min a t  23 "C 
before injection  into  the  column.  The  same  incubation  steps  were fol- 
lowed in  assessing G,a binding  to  phosducin. 
RESULTS 
Phosphorylation State-dependent  Inhibition of '25Z-G,a 
Binding to Rho* by Phosducin 
In  an effort to  understand  the  mechanism of phosducin in- 
hibition of G-protein activation  and  to  assess  the consequences 
of phosducin phosphorylation, direct effects of phosducin on 
1251-G,a binding to Rho" were measured. Phosducin or phos- 
B 
(phosducin] pM 
a b  c d  
X . .  
inhibit '*'I-G,a binding to light-activated  rhodopsin. A, light-in- 
FIG. 1. Phosphorylation of phosducin regulates its ability to 
duced binding of ""I-G,a (0.1 psc) and  G,py (0.1 PM) to  urea-stripped 
ROS membranes  (0.2 PM Rho) was  carried  out  in  the  presence of un- 
phosphorylated (0) or  phosphorylated (0) phosducin at   the concentra- 
tions  indicated  (see  "Experimental  Procedures"). Error  bars  represent 
the  standard  error of data from three  separate  experiments. 100% is 
0.17-0.20  pmol of 1251-G,a boundlpmol of  Rho*. The  solid  line  represents 
a curve fit of the data to the following equation. % bound = loo/ 
(l+([phosducin]/Kv,)"); where  Kn = 0.3 -c 0.05 p~ and  n = 1.6 t 0.2. The 
phosphorylation mixture without phosducin had no effect on "'I-G, 
binding  (data  not  shown).  B,  phosducin  was  phosphorylated  and iso- 
eletric  focusing  was performed as described  under  "Experimental  Pro- 
lane b, similar  stain of phosphorylated  phosducin;  lanes  c  and ,  corre- 
cedures."Lane a ,  Coomassie Blue  stain of unphosphorylated  phosducin; 
sponding  autoradiograph of unphosphorylated  and  phosphorylated 
phosducin, respectively. 
phophosducin was  added  in  increasing  concentrations to Iz5I- 
Gp ,  G,P-y, and  urea-stripped ROS membranes  in '251-G,a bind- 
ing  assays (19). The  binding of lz5I-G,a to Rho* was prevented 
by phosducin  (Fig. lA). At lzsI-Gta and GJ-y concentrations of 
0.1 p ~ ,  half-maximal  inhibition  occurred at -0.3 VM phosducin, 
and  binding  was  totally prevented a t  2 p~ phosducin.  Inhibi- 
tion was cooperative (nspp = 1.6 0.2), consistent with the 
cooperative nature of G, binding  to Rho* (19)  and  indicating 
that phosducin  does  control the concentration of free  GpPy.  In 
light of these  data,  the observed inhibition of G-protein  GTPase 
activity and effector enzyme  activation by phosducin (12,161  is 
best explained by phosducin's blocking G-protein interaction 
with  the  activated receptor. 
When  phosducin was phosphorylated with CAMP-dependent 
protein  kinase  and ATP before assaying for inhibiton of  1251-G,a 
binding to Rho*, no inhibition was found even at phoducin 
concentrations up to 6 PM (Fig. L4). This corresponds to a 
decrease of a t  least 50-fold in phosphophosducin's ability to 
inhibit 1251-Gta binding compared with  that of dephosphophos- 
ducin. 
The  extent of phosducin  phosphorylation under  these condi- 
tions  was  determined by isoelectric focusing (Fig. 1B).  In iso- 
electric focusing gels, three major isoforms of phosducin were 
observed near PI 5.2. These isoforms may  result from sequence 
variations  in phosducin. In  retinal rods, variants of phosducin 
at amino acid position 44 have been reported. One isoform 
contains a His  residue (11, 12,21),  whereas  the second isoform 
Effects of Phosducin  Phosphorylation  on Dansducin  Function 
contains a Pro residue (10, 12). The different isoforms could 
also  result from modifications during purification such as  pro- 
teolytic  cleavage. However, if proteolysis had been  occurring, it 
could not  have been extensive because  no  proteolytic products 
were observed by SDS-PAGE, which could detect  the loss of 
fragments of 1 kDa or larger. Phosphorylation by CAMP-de- 
pendent  protein  kinase  shifted  all isoforms to more acidic PI 
7;alues (compare lanes a and b )  and  an  autoradiograph of the 
gel (lanes c and d )  showed that  all isoforms were  phosphoryl- 
ated (lane d ) .  Moreover, no residual phosducin was detected in 
the  bands corresponding to  unphosphorylated phosducin. Thus, 
it appears  that none of the isoforms are phosphorylated in  the 
purified  phosducin and  that  all isoforms are completely phos- 
phorylated upon treatment  with CAMP-dependent protein ki- 
nase  and ATP. 
The  data  presented  in Fig. 1 indicate that phosducin's ability 
to  inhibit '*'I-G,a binding  to Rho* is decreased  more than 50- 
fold when  phosducin is  in  its phosphorylated state. 
Dephospho- and Phosphophosducin Binding to G,Py- 
Phosducin is known to  interact  with G,Py and  appears  to dis- 
sociate solubilized GtaPy (16). Since  GtPy is  required for high 
affinity binding of G p  to Rho* (22-241, phosducin could block 
G p  binding to Rho" by sequestering G,Py in a phosducin-G,py 
complex. If this  is  the case, then phosphorylation of phosducin 
should  inhibit phosducin-G,py interactions,  ince phos- 
phophosducin did not block 1251-G,dG,py binding to  Rho*. The 
effect of phosducin phosphorylation on the interaction with 
GtPy was directly examined  in a silica gel-based HPLC size 
exclusion column. Unmodified phosducin eluted from an SEC 
250-5 column with a retention time of 8.4 min, which was 
earlier  than  the predicted retention  time for a 28-kDa protein 
(9.6 min, Fig. 2, A and E). This  early  elution could result from 
phosducin  oligomerization or  electrostatic repulsion of phosdu- 
cin by the column matrix.  The  latter possibility appears likely 
because  increasing  the NaCl concentration from 0.5 to 1.0 M 
increased  the  retention of phosducin on the column to  near 
normal for a 28-kDa monomer. Furthermore, sucrose density 
gradient  centrifugation  analysis of phosducin  gave  no apparent 
evidence  for an oligomer. Using bovine serum  albumin, ovalbu- 
min, chymotrypsinogen, and cytochrome c as  standards, phos- 
ducin  exhibited an szo,w value of 2.2 S, which is  somewhat lower 
than expected  for  a  globular protein of 28 kDa. 
G,Py also  exhibited an unexpected elution  rate from the col- 
umn. It  was  much delayed and  eluted at 11.8 min,  later  than 
the  total column  volume  (Fig. 2, B and E). This  retention of 
G,Py on the column seems to  be a result of hydrophobic inter- 
actions with  the column matrix, since increasing  the NaCl con- 
centration  further  increased  the  retention  time of G$y. These 
unusual  interactions of phosducin and G,Py with  the column 
matrix  were exploited to  obtain excellent separation of phos- 
ducin and G,Py on the column. When G,Py was  incubated  with 
phosducin prior to sample injection, G,Py eluted a t  8.4 min, 
overlapping the phosducin peak. This  is evidenced by an in- 
crease  in  the  area  under  the phosducin peak, by a shifting of 
G,Py into  this  peak (Fig. 2F,  lane c), and by the  disappearance 
of G,Py at   the  11.8 min  elution  time (Fig.  2, C and F ,  lane  e). 
Thus,  binding  to phosducin  caused G,Py no longer to  interact 
with  the column matrix  but  to  elute  in a complex with phosdu- 
cin that exhibited  a retention  time  similar  to  that of free phos- 
ducin. This corresponds to  the expected retention  time for a 
Gt/3y.phosducin oligomer of 74  kDa.  A  very small  fraction of the 
G,Py was found a t  elution  times between that of phosducin- 
G,Py and  free G,Py (Fig. 2F, lane d ) ,  suggesting  that  the phos- 
ducin-G$y complex is  quite  stable on the column and  that  the 
column matrix  is  not slowly removing G,Py from the phosducin- 
G,Py complex as  it  passes  through  the column. 
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FIG. 2. HPLC analysis of interactions of phosducin  and G!py. 
HPLC  size exclusion chromatography  and gel analysis of peak  fractlons 
were performed as described under  "Experimental  Procedures."  Elution 
profiles from the size exclusion column are shown as follows:A, 3.3 nmol 
of phosducin; B, 1.1 nmol of G$y; C, 3.3 nmol of phosducin and 1.1 nmol 
G,Py; D ,  3.3 nmol of phosphophosducin, 1.1 nmol of G,Py, 200 units of 
CAMP-dependent protein  kinase,  12 nmol of ATP; E, molecular  mass 
standards  with  the following retention times: 5.8 min, bovine thyro- 
globulin (670 kDa); 7.6 min, bovine y globulin (158 kDa); 8.9 min, 
chicken  ovalbumin (44 kDa);  10.2  min,  horse myoglobin (17  kDa);  and 
11.5 min,  vitamin B-12 (1.35  kDa). F, SDS-PAGE of fractions (a-n) from 
the  chromatograms  as  indicated.  In panel C, phosducin  and G,Py were 
incubated for 5 min a t  23 "C prior to sample injection. In panel D,  
phosphophosducin was prepared according to "Experimental Proce- 
dures,"  and  then G,Py was  added  and  incubated for 5  min a t  23 "C prior 
to  sample injection. SDS-PAGE molecular  mass  standards  are shown 
and  correspond to the following molecular  masses from top to bottom: 
66,45,36,29,  and 24 kDa. 
Next, the  interaction between phosphophosducin and  GJy 
was examined in  the presence of CAMP-dependent protein ki- 
nase  and ATP, which were present to assure  persistent phos- 
ducin  phosphorylation.  (Phosphophosducin was found to be ex- 
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FIG. 3. Phosducin inhibition of lzsI-G,py binding to ROS mem- 
branes. ""I-G,Py (0.35 p ~ )  binding  to  unillummated  urea-stripped ROS 
membranes  (40 p ~ ,  Rho) was  measured at increasing  concentrations of 
phosducin (0) or phosphophosducin (0) as indicated  (see  "Experimental 
Procedures"). The total '?SI-Gtpy in the 2 0 4  sample was 7.0 pmol. 
Error bars represent  the  standard  error f the  data from three  separate 
experiments.  The  data  were  curve fit as  described  under  "Experimental 
Procedures," yielding  a Kd2 value of 0.11 PM for phosducin  binding  to 
'"I-Gtpy and 0.18 PM for phosphophosducin  binding  to lZSI-G,py. The 
saturatlon points for the inhibition were at 0.48 and 0.58 pmol for 
dephospho- and phosphophosducin, respectively. The  curve  fitted  value 
of Kdl for the  binding of 1251-Gtpy to  the  urea-stripped  membranes  was 
2.2 p~ for  dephosphophosducin,  and this  value  was fixed a t  2.2 p~ in 
fitting  the  phosphophosducin curve. 
tremely sensitive to trace amounts of phosphatase activity.) 
After  a  phosducin sample  was phosphorylated, G,Py was  added, 
and  the  mixture  was injected. In  this case, the phosducin peak 
remained  unchanged,  and  the G,py eluted  with  the ATP peak 
(Fig. 2 0 ) .  Gel analysis showed that G,py had been lost from the 
phosducin peak  and  had  reappeared  in  the 11.8 min  peak (Fig. 
3F, lanes j and 1 ). Thus,  in  this column matrix, phosphorylation 
inhibits phosducin's ability  to bind G,&. 
The  data from the size  exclusion  column  gives a qualitative 
comparison of dephospho- and phosphophosducin binding to 
G$y. In  order  to  further  quantify  the differences in  binding 
affinity  between the two forms of phosducin, a second experi- 
mental approach was employed. This  method took advantage of 
the fact that, unlike free G,&, the phosducin-G,py complex 
does not bind to ROS membranes (15). G,Py was  iodinated  with 
['2sIlBolton-Hunter reagent  in  order  to  accurately  determine 
amounts of G,py on the  membrane  and  in  the  supernatant. 
12sI-G,py was  incubated  with  increasing  concentrations of phos- 
ducin in the presence of unilluminated urea-stripped ROS 
membranes a t  a 10-fold excess of Rho over 12sI-G,py. After in- 
cubation,  the ROS membranes were  pelleted, and  the  amount 
of 'ZSI-G,py in  the pellet was  quantified.  In  the absence of phos- 
ducin, 3.2 pmol, or 46%  of the  total "'I-G,py was found in  the 
pellet (Fig. 3). The addition of phosducin inhibited '2sI-G,py 
binding  to  the  membrane  almost c mpletely. Fitting  the  data o
a simple model for 1:l stoichiometric binding of 1251-G,py to 
phosducin indicated  that, at saturation, 0.48 pmol of '2sI-G,py 
were in  the  membrane pellet and  that  the Kd for phosducin 
binding  to 1251-G,py was 0.11 m. Inhibition of 12sI-Gtpy binding 
to  the  membrane  was  not caused by phosducin  competing for 
the  same  membrane  binding  sites a  '2sI-Gtpy because  phosdu- 
B a b c  
L 
binding of 'h-Gtpy (0.35 PM) to unilluminated  urea-stripped ROS mem- 
FIG. 4. G Q competit ion with phosducin for 1261-G,py binding.A, 
branes (40 PM Rho)  was  measured  in the presence (0) and  absence (x) 
of phosducin  (2.0 p) or phosphophosducin (0) at the  concentrations of 
Gp indicated (see "Experimental Procedures"). The  total '*'I-G,py in 
the 20-1.11 sample  was 7.0 pmol. Error bars represent  the  standard  error 
of the  data from two  separate  experiments,  and  these  data  are  repre- 
The  data were fit to the following equation. 1Z61-G,py bound = ((1251-G,py 
sentative of data obtained from three  different  phosducin  preparations. 
max - 1251-G,py min) [G,a]/(Kv. + [Gpl)) + G,Py min;  where lZSI-Gtpy 
max is the  amount bound at  saturating Gta and 12511-G,py min  is the 
amount bound in  the absence of Gp. Fitting  the  data  in  this  manner 
resulted  in K% = 0.39 f 0.2 p~ in  the absence of phosducin, Kv, = 1.8 f 
0.4 p~ in  the presence of dephosphophosducin, and Kv, = 7.5 -t 1.9 p~ in 
the presence of phosphophosducin. B, SDS-PAGE analysis of the bind- 
ing of Gp, G,py, and  phosducin  to  urea-stripped ROS membranes  was 
performed as described under "Experimental Procedures" with 4 p~ 
brane  pellet in  the presence (lane c) or the absence (lane b )  of G,a are 
phosducin, 6 PM G$y, and 16 p~ Gp.  Hypotonic extracts of the mem- 
shown.  The arrow indicates  the  migration position for phosducin. Mo- 
lecular  weight  standards (lane a )  are from top to bottom: 66,45,36, 29, 
24, and 20 kDa. 
cin  did not bind to  the  membrane. SDS-PAGE analysis showed 
< 5% of the  total phosducin was found in  the  membrane pellet 
(Fig. 4B, lane b) .  Thus,  the most compelling explanation of the 
inhibition of 12sI-Gtpy binding  to  the  membrane  is  that  it  re- 
flects  conformational changes  resulting directly from phosdu- 
~in-"~I-G,py  interaction. 
When phosducin was phosphorylated by CAMP-dependent 
protein  kinase, only small  decreases  in  the  binding of '2sI-G,py 
were observed (Kd = 0.18 VM), and the saturation point for 
inhibition of '2sI-Gtpy binding to the  membrane  was  similar 
(0.58 pmol in  the  pellet)  to  that of dephosphophosducin. Thus, 
phosphophosducin bound "'I-G,py nearly as  well as did de- 
phosphophosducin. Iodination did not appear to change the 
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interaction of GJy with phosducin, because similar results 
were  obtained  with  unlabeled G,Py (measured by SDS-PAGE 
analysis of membrane bound and  supernatant fractions). More- 
over, unlabeled  Gtpy competed equally well with 1251-Gtpy for 
phosducin binding  in  membrane  binding  experiments  (data  not 
shown). 
Eff’ect of G p  on Phosducin  Binding to G,py-The  small de- 
crease  in  binding affinity of phosphophosducin  for GtPy could 
blot explain  the  striking difference in migration of  G$y with  the 
two forms of phosducin  on the size exclusion column, nor could 
it explain  the  large difference in  the  ability of dephospho- and 
phosphophosducin to inhibit 1251-GtoJGpy binding to Rho*. 
Thus, it appeared that phosphorylation of phosducin was  regu- 
lating phosducin’s inhibition of G, activation by Rho* at a site 
different  from phosducin-G,py binding.  Therefore, the effect of 
G p  on the binding of dephospho- and phosphophosducin to 
Gtpy  was  measured.  Increasing  amounts of Gta  were  added  to 
‘251-Gtpy and phosducin in  the  membrane  binding  experimental 
format described  above  (Fig. 4A). In  the  absence of phosducin, 
Gta  caused an increase of lZ5I-Gtpy binding  to  unilluminated 
urea-stripped ROS membranes,  as evidenced by an increase  in 
1251-Gtpy in  the  membrane pellet from 2.8 to  4.0 pmol. This 
result  suggests  that  GpPy  binds ROS membranes  with  higher 
affinity than G& alone. In  the presence of 2 I” phosphophos- 
ducin, the  binding of 1251-Gtpy to the  membrane  was  inhibited 
as expected. Only 0.7 pmol of the 1251-Gtpy remained  in  the 
membrane pellet. When Gta was added, a large increase in 
1251-Gtpy binding  to  the  membrane  was observed. ‘251-Gtpy in 
the  membrane pellet increased from 0.7 to 4.0 pmol, reaching 
the level found in  the  absence of phosducin. These  data  indicate 
that G p  does compete with phosphophosducin for binding  to 
G$y, and  that at -5-fold excess G,a the phosphophosducin is 
completely  displaced by Gp .  
G p  competition with dephosphophosducin for 1251-Gtpy bind- 
ing  was more complex. In  the presence of 2 PM dephosphophos- 
ducin, G p  caused a more  modest increase in 1251-Gtpy binding 
to the  membrane (from 0.5 to 2.0 pmol). The  initial  increase  in 
bound 1251-Gtpy paralleled  that of phosphophosducin, but  then 
it leveled off at 2.0 pmol 1251-Gtpy in  the pellet,  compared with 
4.0 pmol in  the  absence of phosducin or with phosphophosdu- 
cin. Thus, this increase  in bound 1251-Gtpy does not  appear  to 
result from direct competition of G p  with dephosphophosducin 
for binding  to 1251-Gtpy. The  increase  also does  not appear to 
result from increased  binding of free 1251-Gtpy in  the presence of 
G p ,  as was observed in  the  absence of phosducin. That effect 
exhibited a Kv, of 0.4 w which is  equal  to  the 1251-Gtpy concen- 
tration,  whereas  the  increased 1251-Gtpy binding  in  the presence 
of dephosphophosducin had a Kv, of 1.8 w. Moreover, very little 
free 1251-Gtpy exists at 2 phosducin and could not account for 
the observed 1.5 pmol increase  in membrane-bound 1251-Gtpy. 
This observation might  suggest  the  formation of phosducin- 
GpPy complexes that bind G,a with lower affinity  than does 
Gtapy,  and which associate  with ROS membranes  with  higher 
affinity than does phosducin-G,py. While phosducin-Gppy 
complexes have  been proposed (12), no compelling evidence for 
such a complex has been presented. SDS-PAGE analysis of 
phosducin binding to the  membrane  pellet  in  the presence of 
excess G$y showed no bound  phosducin in  the  absence or pres- 
ence of G p ,  indicating  that  Gta does not  increase phosducin 
binding to the membrane (Fig. 4B). In contrast, significant 
amounts of both G p  and  Gtpy were  found in  the  membrane 
pellet, and G p  caused an increase  in  Gtpy  binding  to  the mem- 
brane as expected. Thus, the observed increase in 1251-Gtpy 
binding  in  the presence of dephosphophosducin and  Gta  cannot 
be explained by the  formation of a phosducin-Gppy complex. 
An alternative  explanation for the  data  is  that  the different 
FIG. 5. HPLC analysis of interactions of phosducin and Gp. 
HPLC size exclusion chromatography and gel analysis of peak fractions 
was performed as described under “Experimental Procedures.” Elution 
profiles from the size exclusion column are  as follows: A, 0.6 nmol of Gp;  
B,  0.6 nmol of phosducin; C, 0.6 nmol of phosducin and 0.6 nmol of Gp;  
D, 0.6 nmol of phosphophosducin, 0.6 nmol of Gp, 200 units of CAMP- 
dependent protein kinase, 12 nmol  ofATP; E, molecular mass standards 
(see Fig. Z E )  with the following retention times; 5.6 min, bovine thyro- 
globulin; 7.8 min, bovine y globulin; 9.2 min, chicken ovalbumin; 10.5 
min, horse myoglobin; 12.5 min, vitamin B-12. In panel C, phosducin 
and G p  were incubated for 5 min at  23 “C prior to  sample injection. In 
panel D, phosphophosducin was prepared (see “Experimental Proce- 
dures”), and  then G p  was added and incubated for 5 min at  23 “C prior 
to sample injection. 
isoforms of phosducin  compete with G p  for Gtpy  binding with 
different affinities. One isoform might be more readily dis- 
placed from G,Py by Gta  in a manner analogous to  the displace- 
ment of phosphophosducin, whereas  other isoforms might  not 
be displaced by G p .  This could account for the  partial  increase 
in 1251-Gtpy in  the  membrane  pellet when G p  is  added  in  the 
presence of dephosphophosducin. 
Regardless of the  reason  behind  partial competition  between 
dephosphophosducin and  Gta,  the  principal conclusion drawn 
from these  experiments  is  that  the  Gta.Gtpy  interaction is the 
locus at which  phosphorylation  controls  phosducin inhibition of 
G, activation.  Phosphophosducin is displaced  from G,Py  by G p  
and,  therefore, does not  inhibit G, activation by Rho*. In con- 
trast, dephosphophosducin is  not  readily displaced  from  Gtpy 
by G p  and, therefore, blocks G, activation by Rho* through 
sequestration of G,Py 
Assessment of G p  Binding to Phosducin-Phosducin has 
been  shown to  inhibit  the  GTPase  activity of Goa  in  the absence 
of GPy (121, suggesting  that phosducin can bind  Goa  alone.  Size 
exclusion chromatography (Bio-Silect SEC250) was used to  as- 
sess phosducin binding  to  Gta  in  the  absence of Gtpy (Fig. 5). 
G p  eluted a t  10.0 min  in  the absence of phosducin (Fig. 5 A )  
and phosducin eluted at 8.8 min  in  the absence of G p  (Fig. 5B).  
When  the two were  incubated  together prior to injection into 
the column, no change  in  elution  times or peak  areas for either 
phosducin or G p  was observed (Fig. 5C) .  This  is  in  sharp con- 
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FIG. 6. Effect of phosducin on ‘261-G,(u binding to ROS mem- 
branes. The binding of 1251-Gta  (0.35 w) to urea-stripped ROS mem- 
branes (40 VM Rho) was measured in the presence of increasing concen- 
trations of dephospho- (0) or phosphophosducin (0) as indicated (see 
“Experimental Procedures”). The total 1251-G,a in the sample was 7.0 
pmol. Error bars represent the  standard  error of the data from two 
separate experiments and are representative of data from  two different 
phosducin preparations. 
trast to the elution profile of phosducin plus G&, in which all 
the G,Py co-eluted with phosducin (Fig. 2C). In addition, phos- 
phorylation of phosducin with CAMP-dependent protein kinase 
and ATP did not change the phosducin plus Gta elution profile 
(Fig. 5D). 
The possibility of a phosducin-G,a interaction was further 
probed  by examining the effect of phosducin on the intrinsic 
affinity of Gta for  ROS membranes in  the absence of G,Py. Fig. 
6 shows data for ‘251-G,a binding to ROS membranes in  the 
presence of increasing phosducin concentrations. Since urea- 
stripped ROS membranes contain residual amounts of endog- 
enous G$y, the membranes were heat denatured prior to meas- 
uring 1251-Gta binding.2 Phosducin had no effect on 1251-Gta 
binding to the  heat denatured membranes. Despite the addi- 
tion of up to  -20-fold excess of phosducin, no change in  the 
amount of 1251-Gta in  the membrane pellet was observed.  More- 
over, phosphorylation of phosducin did not modify the binding. 
This result should be contrasted with the large decrease in 
membrane bound 1261-GtPy (from 3.2 to 0.5 pmol) upon the 
addition of phosducin. Thus, the  data from Figs. 5 and 6 give  no 
evidence  for a direct interaction between phosducin and Gp. 
The reason for the  apparent discrepancy between these data 
and the Goa GTPase data mentioned above (12) is not obvious. 
Heat denaturation decreased the amount of lZ5I-Gta in  the mem- 
brane pellet from 4.2 -c 0.3 pmol ( n  = 3) to 2.0 -c 0.2 pmol ( n  = 4) under 
these conditions.  Adding  back  exogenous G$y restored lZ5I-Gta binding 
to  the membrane, with a Kv, of 0.1 VM, and the effect saturated at 5.6 
pmol of the lZ5I-Gta in  the pellet. Heat denaturation of the membranes 
had  little effect on G,py binding. 3.1 -c 0.05 pmol ( n  = 4) and 3.6 -c 0.06 
pmol ( n  = 2) of the 1251-G,py were in  the membrane pellet in unheated 
and heat denatured membranes, respectively. Thus, it appears that 
heating urea-stripped ROS membranes in  this manner denatures the 
-4% of the endogenous G,Py that remains after urea stripping. These 
results also suggest that GtPy does not bind to proteins in the ROS 
membrane, which would be denatured by heating. Moreover,  endoge- 
nous Gtpy  does not significantly affect the binding of exogenous Iz5I- 
Gtpr to  the membranes under the condition of excess  G,py binding sites 
used in these experiments. 
However, it is possible that G p  and Goa differ in their ability to  
bind phosducin so that phosducin interacts differently with 
different G-proteins. 
DISCUSSION 
Phosducin inhibits G, activation by blocking its binding to  
Rho*, apparently  as  a  result of G,Py sequestration in a phos- 
ducin-G$y  complex. A single G,Py can act catalytically to acti- 
vate many Gps, because once the Rho*.G,c@y  complex disso- 
ciates upon GTP binding, the G,Py is freed to interact with 
other Gps (23). However, the  rate of G p  activation by Rho* 
depends on the concentration of free G&, with maximal acti- 
vation occurring at a 1:l ratio of G,a to G,Py (24). Therefore, 
sequestering free G,Py in  a complex with phosducin would de- 
crease the  rate of G p  activation by  Rho* without totally abol- 
ishing it. This type of down-regulation is precisely what is 
observed in light-adapted retinal rods (reviewed in Ref. 25). 
The phosducin concentration in  retinal rods is estimated to  be 
equal to that of  G,  (151, so there  is sufficient phosducin present 
to substantially decrease G, activation. 
Although it  has been suggested that phosphorylation of phos- 
ducin  may regulate its function in retinal rods (161, the conse- 
quences of phosphorylation had been unclear. This may  reflect 
the fact that  the binding affinities of phospho- and dephos- 
phophosducin  for purified G,Py are similar. The data presented 
here show that phosphorylation of phosducin regulates its abil- 
ity to block G p  interaction with G$y.  Phosphophosducin binds 
G,Py with similar affinity to  dephosphophosducin but  in  a con- 
formation that allows Gta to  interact with G,Py and displace 
phosphophosducin. Once formed, the  GpPy can be  effectively 
activated by Rho*. In  the unphosphorylated state, phosducin 
interacts with GtPy in  a conformation that excludes Gta from 
accessing its binding site on G,Py, and, therefore, G,a cannot 
displace  dephosphophosducin. 
Evidence  for two different conformations of phosducin-G$y, 
depending on the phosphorylation state of phosducin stems 
from their contrasting behavior on the size  exclusion  column. 
G,Py in the absence of phosducin interacted with the column 
matrix; but  in  the presence of phosducin, G,Py was bound in  a 
conformation that did not allow it to interact with the column 
matrix, and the two proteins migrated in a phosducin-G$y 
complex.  When  phosducin  was phosphorylated, despite having 
a similar affinity for G&, phosphophosducin and GtPy  were 
separated on the column. The best explanation for this  result is 
that phosphophosducin  bound G,Py in a different conformation, 
which  allowed G,Py to interact with the column matrix. Such 
an interaction would  effectively  pull  GtPy  from  phosphophos- 
ducin during  the column run.  It is possible that G p  acts  in  a 
manner similar to the column matrix in distinguishing be- 
tween dephospho- and phosphophosducin-G,Py  complexes. 
From these findings, a model depicting phosducin as  a phos- 
phorylation-dependent regulator of light-activated G-protein 
mediated-signaling in retinal rods can now  be proposed  (Fig.  7). 
In unilluminated rods, cyclic nucleotide levels are elevated (26- 
28), cAMP-dependent protein kinase is active (29, 301, and 
phosducin remains phosphorylated (17). Under these condi- 
tions, phosphophosducin cannot compete with G p  for G$y 
binding. Therefore, G p  and G,Py are maximally associated in 
their active heterotrimeric state. After illumination, cyclic 
nucleotide  levels fall (28, 31, 321,  CAMP-dependent protein ki- 
nase  is inactivated, and phosducin is dephosphorylated by un- 
opposed  rod phosphatases (17,331.  Dephosphophosducin binds 
GtPy and prevents Gta from associating with G$y, thereby 
constraining Rho* activation of G p  and slowing the  rate of 
cGMP-phosphodiesterase activation by Gta.GTP. Thus, phos- 
ducin  could act in concert with increased guanylyl cyclase (34) 
and rhodopsin kinase (35) activities (following light-induced 
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clic nucleotides, the CAMP-dependent protein kinase activity, 
and,  thus,  the phosphorylation state of phosducin. 
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FIG. 7. Model of phosducin  regulation of G-protein  dynamics. 
The sketch depicts the proposed competition between G p  and phosdu- 
cin for binding to G&. When phosducin is not phosphorylated, it binds 
blocking G,a binding to G&. When phosducin is phosphorylated, it still 
G,py in a conformation that masks the Gp binding site, effectively 
binds G&, but it does not mask the G p  binding site. Thus, in the 
presence of Gp ,  phosphophosducin is displaced, and G~3-y reassociates 
with Gp. See text for further details of the model. Pd, phosducin; 
phosphatase, phosphatase 2A (of which phosducin has been proposed  to 
be a substrate (33)). 
decreases in [Ca"]) to facilitate rod recovery from the light 
response. In  addition, phosducin could also  function to down- 
regulate  subsequent  light responses until  that point in  time 
when cyclic nucleotide levels have been fully restored  and phos- 
ducin has been rephosphorylated. Once phosphorylated, the 
phosphophosducin-G,py complex becomes unstable  in  the pres- 
ence of Gp .  G,a binds  to G,Py and displaces phosphophosducin. 
Thus, the system is returned to its dark-adapted state and 
GpPy is  able  to  interact efficiently with a Rho* produced by the 
next photon absorption. 
Growing insight into the complexity and number of GPy 
functions has provided a compelling context within which to 
study  the  ubiquitous G-protein regulator phosducin. Phospho- 
rylation state-dependent inhibition of Ga  and GPy interactions 
may be a general mechanism of action of phosducin for all 
G-proteins.  Phosducin  might  also block activation of enzymes 
that  are directly  activated by Gpy,  such as S-adrenergic  receptor 
kinase (51, type I1 adenylyl cyclase (6,7), and phospholipase C-P 
(8,9). Moreover, the effects ofphosducin on its target G-proteins 
are  in  turn subject to  feedback regulation by the  impact of the 
activated G-proteins on adenylyl cyclase and phosphodiester- 
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